The APOE*4 allele of the apolipoprotein E gene (APOE) is an important risk factor for Alzheimer's disease. It has been suggested that levels of apolipoprotein E (apoE) in plasma are increased in Alzheimer's disease. In this population-based study, we found that serum apoE levels were lower in Alzheimer patients compared to non-demented controls (0.75 μmol/l (SD 0.35), vs. 0.83 μmol/l (SD 0.40), P < 0.05). This finding is in accordance with lower serum apoE levels as observed in carriers of the APOE*4 allele, who are over-represented in Alzheimer's disease. After adjustment for age, sex, total protein, albumin level, body mass index and the APOE genotype, the difference in serum apoE levels largely disappeared. Our population-based study suggests that the differences in serum apoE level between Alzheimer patients and controls are mainly the result of differences in the distribution of the APOE genotype.

, , , , ,
doi.org/10.1016/S0304-3940(98)00339-5, hdl.handle.net/1765/60612
Neuroscience Letters
Erasmus MC: University Medical Center Rotterdam

Slooter, A., de Knijff, P., Hofman, A., Cruts, M., Breteler, M., van Broeckhoven, C., … van Duijn, C. (1998). Serum apolipoprotein e level is not increased in Alzheimer's disease: The Rotterdam study. Neuroscience Letters, 248(1), 21–24. doi:10.1016/S0304-3940(98)00339-5